Publication

Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and meta-analysis

de Zwart, P. L., van Dijken, B. R., Holtman, G. A., Stormezand, G. N., Dierckx, R. A., van Laar, P. J. & van der Hoorn, A., 20-Sep-2019, In : Journal of Nuclear Medicine.

Research output: Contribution to journalArticleAcademicpeer-review

APA

de Zwart, P. L., van Dijken, B. R., Holtman, G. A., Stormezand, G. N., Dierckx, R. A., van Laar, P. J., & van der Hoorn, A. (2019). Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and meta-analysis. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.119.233809

Author

de Zwart, Paul L ; van Dijken, Bart Rj ; Holtman, Gea A ; Stormezand, Gilles N ; Dierckx, Rudi A ; van Laar, Peter Jan ; van der Hoorn, Anouk. / Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma : a systematic review and meta-analysis. In: Journal of Nuclear Medicine. 2019.

Harvard

de Zwart, PL, van Dijken, BR, Holtman, GA, Stormezand, GN, Dierckx, RA, van Laar, PJ & van der Hoorn, A 2019, 'Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and meta-analysis', Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.119.233809

Standard

Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma : a systematic review and meta-analysis. / de Zwart, Paul L; van Dijken, Bart Rj; Holtman, Gea A; Stormezand, Gilles N; Dierckx, Rudi A; van Laar, Peter Jan; van der Hoorn, Anouk.

In: Journal of Nuclear Medicine, 20.09.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

de Zwart PL, van Dijken BR, Holtman GA, Stormezand GN, Dierckx RA, van Laar PJ et al. Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and meta-analysis. Journal of Nuclear Medicine. 2019 Sep 20. https://doi.org/10.2967/jnumed.119.233809


BibTeX

@article{27738f024ae44d8abb3eabf0bbdf847d,
title = "Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: a systematic review and meta-analysis",
abstract = "Background: Post-treatment high-grade gliomas are usually monitored with contrast-enhanced MRI, but its diagnostic accuracy is limited as it cannot adequately distinguish between true tumor progression and treatment-related changes. According to recent response assessment in neuro-oncology (RANO) recommendations PET overcomes this limitation. However, it is currently unknown which tracer yields the best results. Therefore, a systematic review and meta-analysis were performed to compare the diagnostic accuracy of the different PET tracers in differentiating tumor progression from treatment-related changes in high-grade glioma patients. Methods: Pubmed, Web of Science and Embase were searched systematically. Study selection, data extraction and quality assessment were performed independently by two authors. Meta-analysis was performed using a bivariate random effects model when ≥ 5 studies were included. Results: 39 studies (11 tracers) were included in the systematic review. 18F-FDG (12 studies, 171 lesions) showed a pooled sensitivity and specificity of 84{\%} (95{\%}CI 72-92) and 84{\%} (69-93), respectively. 18F-FET (7 studies, 172 lesions) demonstrated a sensitivity of 90{\%} (81-95) and specificity of 85{\%} (71-93). 11C-MET (8 studies, 151 lesions) sensitivity was 93{\%} (80-98) and specificity was 82{\%} (68-91). The number of included studies for the other tracers were too low to combine, but sensitivity and specificity ranged between 93-100{\%} and 0-100{\%} for 18F-FLT, 85-100{\%} and 72-100{\%} for 18F-FDOPA and 100{\%} and 70-88{\%} for 11C-CHO, respectively. Conclusion:18F-FET and 11C-MET, both amino-acid tracers, showed a comparable higher sensitivity than 18F-FDG in the differentiation between tumor progression and treatment-related changes in high-grade glioma patients. The evidence for other tracers is limited, thus 18F-FET and 11C-MET are preferred when available. Our results support the incorporation of amino-acid PET tracers for the treatment evaluation of high-grade gliomas.",
author = "{de Zwart}, {Paul L} and {van Dijken}, {Bart Rj} and Holtman, {Gea A} and Stormezand, {Gilles N} and Dierckx, {Rudi A} and {van Laar}, {Peter Jan} and {van der Hoorn}, Anouk",
note = "Copyright {\circledC} 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2019",
month = "9",
day = "20",
doi = "10.2967/jnumed.119.233809",
language = "English",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "SOC NUCLEAR MEDICINE INC",

}

RIS

TY - JOUR

T1 - Diagnostic accuracy of positron emission tomography tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma

T2 - a systematic review and meta-analysis

AU - de Zwart, Paul L

AU - van Dijken, Bart Rj

AU - Holtman, Gea A

AU - Stormezand, Gilles N

AU - Dierckx, Rudi A

AU - van Laar, Peter Jan

AU - van der Hoorn, Anouk

N1 - Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2019/9/20

Y1 - 2019/9/20

N2 - Background: Post-treatment high-grade gliomas are usually monitored with contrast-enhanced MRI, but its diagnostic accuracy is limited as it cannot adequately distinguish between true tumor progression and treatment-related changes. According to recent response assessment in neuro-oncology (RANO) recommendations PET overcomes this limitation. However, it is currently unknown which tracer yields the best results. Therefore, a systematic review and meta-analysis were performed to compare the diagnostic accuracy of the different PET tracers in differentiating tumor progression from treatment-related changes in high-grade glioma patients. Methods: Pubmed, Web of Science and Embase were searched systematically. Study selection, data extraction and quality assessment were performed independently by two authors. Meta-analysis was performed using a bivariate random effects model when ≥ 5 studies were included. Results: 39 studies (11 tracers) were included in the systematic review. 18F-FDG (12 studies, 171 lesions) showed a pooled sensitivity and specificity of 84% (95%CI 72-92) and 84% (69-93), respectively. 18F-FET (7 studies, 172 lesions) demonstrated a sensitivity of 90% (81-95) and specificity of 85% (71-93). 11C-MET (8 studies, 151 lesions) sensitivity was 93% (80-98) and specificity was 82% (68-91). The number of included studies for the other tracers were too low to combine, but sensitivity and specificity ranged between 93-100% and 0-100% for 18F-FLT, 85-100% and 72-100% for 18F-FDOPA and 100% and 70-88% for 11C-CHO, respectively. Conclusion:18F-FET and 11C-MET, both amino-acid tracers, showed a comparable higher sensitivity than 18F-FDG in the differentiation between tumor progression and treatment-related changes in high-grade glioma patients. The evidence for other tracers is limited, thus 18F-FET and 11C-MET are preferred when available. Our results support the incorporation of amino-acid PET tracers for the treatment evaluation of high-grade gliomas.

AB - Background: Post-treatment high-grade gliomas are usually monitored with contrast-enhanced MRI, but its diagnostic accuracy is limited as it cannot adequately distinguish between true tumor progression and treatment-related changes. According to recent response assessment in neuro-oncology (RANO) recommendations PET overcomes this limitation. However, it is currently unknown which tracer yields the best results. Therefore, a systematic review and meta-analysis were performed to compare the diagnostic accuracy of the different PET tracers in differentiating tumor progression from treatment-related changes in high-grade glioma patients. Methods: Pubmed, Web of Science and Embase were searched systematically. Study selection, data extraction and quality assessment were performed independently by two authors. Meta-analysis was performed using a bivariate random effects model when ≥ 5 studies were included. Results: 39 studies (11 tracers) were included in the systematic review. 18F-FDG (12 studies, 171 lesions) showed a pooled sensitivity and specificity of 84% (95%CI 72-92) and 84% (69-93), respectively. 18F-FET (7 studies, 172 lesions) demonstrated a sensitivity of 90% (81-95) and specificity of 85% (71-93). 11C-MET (8 studies, 151 lesions) sensitivity was 93% (80-98) and specificity was 82% (68-91). The number of included studies for the other tracers were too low to combine, but sensitivity and specificity ranged between 93-100% and 0-100% for 18F-FLT, 85-100% and 72-100% for 18F-FDOPA and 100% and 70-88% for 11C-CHO, respectively. Conclusion:18F-FET and 11C-MET, both amino-acid tracers, showed a comparable higher sensitivity than 18F-FDG in the differentiation between tumor progression and treatment-related changes in high-grade glioma patients. The evidence for other tracers is limited, thus 18F-FET and 11C-MET are preferred when available. Our results support the incorporation of amino-acid PET tracers for the treatment evaluation of high-grade gliomas.

U2 - 10.2967/jnumed.119.233809

DO - 10.2967/jnumed.119.233809

M3 - Article

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

ER -

ID: 97263610